POPULARITY
Categories
103 episodes with annual meetings
111 episodes with annual meetings
87 episodes with annual meetings
85 episodes with annual meetings
54 episodes with annual meetings
66 episodes with annual meetings
56 episodes with annual meetings
53 episodes with annual meetings
49 episodes with annual meetings
38 episodes with annual meetings
39 episodes with annual meetings
25 episodes with annual meetings
29 episodes with annual meetings
56 episodes with annual meetings
29 episodes with annual meetings
19 episodes with annual meetings
23 episodes with annual meetings
26 episodes with annual meetings
23 episodes with annual meetings
37 episodes with annual meetings
25 episodes with annual meetings
30 episodes with annual meetings
19 episodes with annual meetings
14 episodes with annual meetings
17 episodes with annual meetings
13 episodes with annual meetings
16 episodes with annual meetings
16 episodes with annual meetings
15 episodes with annual meetings
15 episodes with annual meetings
13 episodes with annual meetings
14 episodes with annual meetings
16 episodes with annual meetings
11 episodes with annual meetings
10 episodes with annual meetings
11 episodes with annual meetings
19 episodes with annual meetings
15 episodes with annual meetings
11 episodes with annual meetings
13 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
17 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
14 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
8 episodes with annual meetings
14 episodes with annual meetings
12 episodes with annual meetings
7 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
11 episodes with annual meetings
14 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
9 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
13 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
14 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
10 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
20 episodes with annual meetings
3 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
7 episodes with annual meetings
2 episodes with annual meetings
6 episodes with annual meetings
2 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
10 episodes with annual meetings
3 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
9 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
12 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
10 episodes with annual meetings
2 episodes with annual meetings
4 episodes with annual meetings
60 episodes with annual meetings
3 episodes with annual meetings
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Ellen Barlis, Chief Financial Officer, NYC Health + Hospitals/Jacobi/North Central Bronx. Ellen shares insights on reducing readmissions through interdisciplinary collaboration, addressing Medicaid funding challenges, and leading with intention and data-driven decision making in one of the nation's most complex care environments.
Ryan Dunn, co-president and CEO of Alliance Flooring, and Kemp Harr discuss the buying group's recent in Park City, Utah. Listen to the interview to learn more about the timing of the meeting and the awards that were given out to both the members and the suppliers.
Premier Li Qiang said on Wednesday that in the face of global challenges, countries around the world should make the economic "pie" bigger through open and win-win cooperation rather than playingzero-sum games or following the law of the jungle.中国国家总理李强周三表示，面对全球性挑战，世界各国应通过开放共赢的合作，做大经济“蛋糕”，而不是玩零和游戏或遵循丛林法则Li made the remarks in an address delivered at the opening of the World Economic Forum's 16th Annual Meeting of the New Champions, also known as the Summer Davos, in Tianjin.李在天津举行的世界经济论坛第16届新领军者年会（又称夏季达沃斯）开幕式上发表讲话。He said that the global economic and trade landscape is undergoing profound changes, driven by factors such as geopolitics, technological innovation and structural shifts.Li called on the international community to take constructive actions in carrying out international economic and trade cooperation.他说，在地缘政治、技术创新和结构性转变等因素的推动下，全球经贸格局正在发生深刻变化。李呼吁国际社会采取建设性行动，开展国际经贸合作。"Constructive actions mean we need to proactively take more practical measures to safeguard free trade and multilateralism and promote the stable development of the world economy," Li said.李说：“建设性行动意味着我们需要积极采取更多切实可行的措施，维护自由贸易和多边主义，促进世界经济的稳定发展。”Noting that it is normal for disputes and differences to arise in economic and trade exchanges among countries, the premier said that as long as countries engage in dialogue and consultation based on mutual respect, solutions can always be found.总理指出，国家间经贸交流中出现争端和分歧是正常的，只要各国在相互尊重的基础上进行对话和协商，总能找到解决方案。"We need to strengthen macroeconomic policy coordination and ensure the stability and smooth functioning of global industrial and supply chains. Closer cooperation will help enhance the security and resilience of development for all countries," he added.他补充道：“我们需要加强宏观经济政策协调，确保全球产业链和供应链的稳定和顺利运行。更紧密的合作将有助于提高各国发展的安全性和韧性。”Saying that China is confident in and capable of maintaining rapid economic growth, Li expressed the country's commitment to do whatever it can to help tackle the difficulties and challenges facing the global economy.李说，中国有信心也有能力保持经济快速增长，中国承诺将尽一切努力帮助应对全球经济面临的困难和挑战。Over the years, no matter how the international environment has changed, China's economy has consistently maintained good momentum, Li said.李说，多年来，无论国际环境如何变化，中国经济始终保持良好势头。He noted that China's gross domestic product grew 5.4 percent year-on-year in the first quarter of 2025, despite facing significantly heightened external shocks this year.他指出，尽管今年面临着显著加剧的外部冲击，但中国2025年第一季度国内生产总值同比增长5.4%。"Key economic indicators continued to improve in the second quarter, and I noticed that international institutions have recently raised their expectations for China's economic growth," he said. "China's economic development is not about short-term spurts, but sustained progress toward long-term goals."他说：“关键经济指标在第二季度继续改善，我注意到国际机构最近提高了对中国经济增长的预期。”“中国的经济发展不是短期的爆发，而是朝着长期目标的持续进步。”He pledged that China's market will continue to expand in size and improve in quality, saying that this will create new room for growth and help reverse the downturn in the global economy.他承诺，中国市场将继续扩大规模，提高质量，这将为增长创造新的空间，并有助于扭转全球经济的衰退。China is moving toward becoming a high-income country as a whole, as the demand for consumption upgrade is robust in the world's second-largest consumption market, he said.他说，随着世界第二大消费市场对消费升级的需求强劲，中国整体上正在向高收入国家迈进。The country is striving to develop itself into a mega-sized consumption powerhouse on top of being a manufacturing powerhouse, which, the premier said, will create vast new market opportunities for businesses around the world.总理表示，中国正在努力发展成为制造业强国之外的大型消费强国，这将为世界各地的企业创造巨大的新市场机会。Noting that China's tech innovation has an open-source feature, the premier said the country is willing to share its original technologies and innovative scenarios with the world.总理指出，中国的技术创新具有开源特征，并表示中国愿意与世界分享其原创技术和创新方案。He reiterated the country's commitment to fostering a first-class, market-oriented business environment governed by a sound legal framework, saying it always keeps its doors wide open and warmly welcomes businesses from all countries to invest in China and grow with China.他重申，中国致力于在健全的法律框架下营造一流的、以市场为导向的营商环境，始终敞开大门，热烈欢迎各国企业来华投资，与中国共同发展。Featuring the theme "Entrepreneurship for a New Era", the event, held from Tuesday to Thursday, has gathered over 1,700 leading figures from more than 90 countries and regions to explore how entrepreneurship and emerging technologies can unlock more dynamic and resilient economies.该活动以“新时代创业”为主题，于周二至周四举行，汇集了来自90多个国家和地区的1700多名领军人物，探讨创业和新兴技术如何释放更具活力和弹性的经济。While chairing the event, World Economic Forum President Borge Brende called for international cooperation to address global challenges, and expressed an optimistic outlook on China's economic prospects.世界经济论坛主席博格·布伦德在主持活动时呼吁国际合作应对全球挑战，并对中国经济前景表示乐观。Brende said that the challenges the world faces today—from the development of artificial intelligence to supply chain stability, and from green transition to the skills for the future—require countries to "move from competition to cooperation, from fragmentation to collaboration".Brende说，当今世界面临的挑战——从人工智能的发展到供应链的稳定，从绿色转型到未来的技能——要求各国“从竞争转向合作，从碎片化转向协作”。"China has long been a vital partner in this regard. Its entrepreneurial ecosystem, particularly in areas like artificial intelligence, the digital economy, advanced manufacturing, green innovation and others, continues to be a powerful driver of global growth," he said.Brende说，当今世界面临的挑战——从人工智能的发展到供应链的稳定，从绿色转型到未来的技能——要求各国“从竞争转向合作，从碎片化转向协作”。On Wednesday afternoon, Li held a symposium with representatives of the global business community attending the Summer Davos in Tianjin.周三下午，李在天津与出席夏季达沃斯论坛的全球工商界代表举行座谈会。Li assured the business executives that China is committed to providing a stable development environment and a predictable policy environment for enterprises, and encouraged foreign companies to develop technological cooperation and collaborative innovation in China.李向企业高层保证，中国致力于为企业提供稳定的发展环境和可预测的政策环境，并鼓励外国公司在中国开展技术合作和协同创新。Speaking at the meeting, Dave West, president for the Asia-Pacific, Japan and Greater China of Cisco, a worldwide technology leader in the United States, expressed his confidence about development prospects in China and his hope for a stable relationship between the US and China.美国全球技术领导者思科亚太、日本和大中华区总裁戴夫·韦斯特在会上表示，他对中国的发展前景充满信心，希望美中关系稳定。"We are confident that the Chinese market will continue to create significant and exciting opportunities as the country advances toward its high-quality development goals," West said. "I believe the global economy will be stronger with the US and China working together. And the stable US-China relations will bring mutual benefit, not just to our two countries."韦斯特说：“我们相信，随着中国向高质量发展目标迈进，中国市场将继续创造重大而令人兴奋的机遇。”。“我相信，随着美中两国的共同努力，全球经济将更加强大。稳定的美中关系将带来互利共赢，而不仅仅是我们两国。”Michael Gelchie, CEO of Louis Dreyfus Co, a leading merchant and processor of agricultural goods from the Netherlands, said that his company continues to be bullish about the Chinese market and looks forward to injecting fresh growth momentum into global agricultural trade.荷兰领先的农产品贸易商和加工商Louis Dreyfus Co的首席执行官Michael Gelchie表示，他的公司继续看好中国市场，并期待为全球农产品贸易注入新的增长动力。"Amid the complex challenges facing the world, China's role as a stabilizing force is more critical than ever," he said.他说：“在世界面临的复杂挑战中，中国作为稳定力量的作用比以往任何时候都更加关键。”。geopoliticsn.地缘政治short-term spurtsn.短期冲刺
In this episode of SurgOnc Today, Dr. Miral Grandhi of Rutgers University and Dr. Neha Lad of Mount Sinai Medical Center—both members of the HPB Disease Site Working Group—provide a curated summary of the most impactful hepato-pancreato-biliary malignancy papers presented at the Society of Surgical Oncology's 2025 Annual Meeting in Tampa, Florida. The discussion is moderated by Dr. Patricio Polanco of UT Southwestern Medical Center, who also serves as Vice Chair of the HPB Disease Site Working Group.
Dr Neeraj Agarwal from the University of Utah Huntsman Cancer Institute in Salt Lake City, Dr Andrew J Armstrong from Duke Cancer Institute in Durham, North Carolina, Dr Himisha Beltran from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Fred Saad from the University of Montreal Hospital Center in Québec, Canada, and Dr Rana R McKay from the UC San Diego Moores Cancer Center discuss recent updates on available and novel treatment strategies for prostate cancer. CME information and select publications here.
This year's World Economic Forum Annual Meeting of the New Champions in Tianjin convenes about 1,700 representatives from over 90 countries and regions. They're here to seek answers to some of the most pressing issues of our times. Given today's geopolitical uncertainties, rivalries and increasing tension in the Middle East, what is the latest forecast and outlook on the global economy? What is the future of multilateralism? How do they assess the performance of the Chinese economy as of late?
This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Shrey Kapoor, Chief Executive Officer of MedSetGo. Shrey shares his powerful personal journey into healthcare innovation and discusses how AI is reshaping hospital workflows—especially in case management, discharge planning, and patient throughput—to drive greater efficiency and improve outcomes.This episode is sponsored by MedSetGo.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Dr. Zafar Chaudry, Senior Vice President, Chief Digital Officer and Chief AI and Chief Information Officer, Seattle Children's. Dr. Chaudry shares how his team is transforming pediatric care through cloud-based data analytics, AI-driven opioid reduction, and a flexible, people-first approach to leadership.
Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12) Current Treatment for Metastatic HSPC — Dr Armstrong (26:12) Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31) Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51) Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11) CME information and select publications
The World Economic Forum's Annual Meeting of the New Champions, often called Summer Davos, is taking place in Tianjin, a major coastal city in northern China. Chinese Premier Li Qiang attended the Opening Plenary and delivered an address. The President of Ecuador, Prime Ministers of Singapore, Kyrgyzstan, Senegal, and Vietnam are attending, together with 1,700 representatives from over 90 countries and regions. As China contributes around 30% of global growth annually, what opportunities will deeper global engagement with its market and innovation ecosystem bring? Why has AI become the buzzword throughout the meeting?
This week at NSTA: The Bus Stop - Executive Director Curt Macysyn welcomes back NSTA President Dan Kobussen, Owner of Kobussen Buses, for his final podcast as president. Dan takes us through the early days of Kobussen Buses and reflects on his earliest memories in the school bus industry. He then recaps his two-year tenure as NSTA President, highlighting key moments such as the return of the School Bus Driver International Safety Competition, the 2024 Annual Meeting & Convention in Nashville, TN, the 2025 Midwinter Meeting in Maui, HI, and the successes of the NSTA Capitol Hill Bus-In. Curt and Dan also discuss the challenges contractors faced during the COVID-19 pandemic and what effect that time had on the industry. The conversation shifts to key takeaways from the recent NSTA Strategic Planning Session, and Dan highlights how NSTA represents its members at both the federal and local levels and offers ways for listeners to get involved and support the association. The episode concludes with Dan sharing his vision for the future of student transportation.Support the show
Tonight's show features an assortment of guests as we take a deep-dive into the National Weather Association - what it is, and why it matters. In addition, we examine how the NWA is evolving in its 50th year. We will talk about the NWA Road Map, the critical role of the NWA seals (both broadcast and digital), the power of professional service and volunteering, and the future of trusted weather communication in a changing media environment. James Jessel is a friend of the podcast and works with Guest Booking Officer Bill Murray. He works for Pinnacle Communications Corporation as National Account Manager and joins us tonight as Guest Panelist. James, it is good to see you! Becca Mazur is the 2025 President of the National Weather Association. She's been active with the organization since 2014. She works in Anchorage, Alaska, where she specializes in integrating new science, forecast methods and tools/operational forecasting. She holds degrees from Northern Illinois University and Colorado State University. We are also honored to be joined tonight by Matt Beitscher, who is one of the lead meteorologists with the NWS in St. Louis. He is the Commissioner of Committees for the NWA. Matt, it's great to have you join us tonight! Kendra Kent also joins the gang tonight for our discussion and is the Chief Meteorologist Fox Carolina News in Greenville, South Carolina. She is a long-time NWA seal holder and Emmy nominee. She was named the 2024 South Carolina Weathercaster of the Year. She's also known for her community service and animal rescue work. It's an honor to have you join us tonight, Kendra. Last but certainly not least in order of their appearance, Isaac Williams joins us from WANF-TV in Atlanta Georgia where he is a broadcast on-air meteorologist. He was formerly the Chief Meteorologist at WCBI-TV in Columbus, Mississippi. He's also an instructor at Mississippi State and is currently pursuing his PhD in Earth and Atmospheric Science from Mississippi State. Thanks for joining us, Isaac! Our email officer Jen is continuing to handle the incoming messages from our listeners. Reach us here: email@weatherbrains.com. Memorable New England tropical systems this millennium (25:30) December 16th, 2000 Tuscaloosa tornado (29:00) Becca Mazur's most rewarding projects in meteorology (33:00) Notable professional challenges in meteorology (36:00) Difficulties of time management in a fast paced/digital world (39:30) Dr. George Fischbeck's legacy and passion for weather and its impact on James Jessel (46:10) How did James Spann get into the NWA/History of the NWA? (01:06:45) Preparations for 50th Anniversary/Huntsville NWA meeting September 6th-10th 2025 (01:09:00) "A Brave New World" topic of discussion at NWA meeting (01:14:00) The RON (Research Operation Nexus) (01:18:00) Creation of the NWA Digital Seal/Bill Murray's inaugural Seal (01:21:30) NWA Roadmap Initiative (01:31:00) The Astronomy Outlook with Tony Rice (No segment this week) This Week in Tornado History With Jen (01:34:24) E-Mail Segment (01:35:35) and more! Web Sites from Episode 1014: 2025 Annual Meeting in Huntsville, AL - National Weather Association National Weather Association on X Isaac Williams on X Matt Beitscher on X Kendra Kent on X Picks of the Week: Becca Mazur - Terrifying video of the deadly Enderlin, ND tornado James Aydelott - My Perfect Weather Jen Narramore - Cass County Sheriff's Office identifies victims in deadly Enderlin tornado Jen Narramore - Tornado kills three in upstate NY, including twin sisters Rick Smith - Automated Data Plotter Troy Kimmel - Foghorn Kim Klockow-McClain - Foghorn John Gordon - MetLink - Royal Meteorological Society Local Winds Bill Murray - Foghorn James Spann - Brian Emfinger on X: Site of deadly tornado from east of Enderlin, ND The WeatherBrains crew includes your host, James Spann, plus other notable geeks like Troy Kimmel, Bill Murray, Rick Smith, James Aydelott, Jen Narramore, John Gordon, and Dr. Kim Klockow-McClain. They bring together a wealth of weather knowledge and experience for another fascinating podcast about weather.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Tiffany Miller, Chief Executive Officer, Yoakum Community Hospital. Tiffany shares how her team is cultivating a vibrant organizational culture through leadership development while navigating challenges like Medicare Advantage reimbursement and preparing a compassionate, resilient workforce for the future.
PQS by Innovaccer Associates Brittany Boyd and Ray Arizmendi team up to chat about highlights from the Pharmacy Quality Alliance Meeting (PQA) 2025. Brittany Boyd, PQS Associate Director, Pharmacy Training and Support, and Ray Arizmendi, PQS Director of Customer Success, cover PQA event vibes and conference structure. They talk about sessions they enjoyed and the PQS by Innovaccer unveiling of EQUIPP Copilot.
Dr. Ricky Jones, Professor of Pan African Studies at the University of Louisville, author and political analyst, speaks his mind at the Louisville League of Women Voters Annual Meeting, held June 26, 2025, on a number of topics including what he views as race-based hypocrisy, misinformation and interference in academic affairs on the part of Kentucky local and state government.
At the League of Women Voters of the Kewanee Area's 79th annual meeting on June 18, 2025, Daniela Lozano and Lovondi Jordan, along with Mayor Gary Moore, highlighted the ongoing efforts of the Kewanee Commission on Human Relations. The commission is dedicated to reducing prejudice and promoting equality within the community, partnering with local organizations to advance its mission. Monthly meetings are held at Kewanee City Hall, welcoming public participation. The Kewanee Commission on Human Relations remains committed to fostering understanding and respect among all residents. Its mission is to eliminate prejudice, intolerance, bigotry, and discrimination in the city. The commission collaborates with local civic, religious, and educational groups to achieve these goals. Members such as Jessica Fornander, Taurean Bond, Liz Bermudez, Kari Clark, Daniela Lozano, and Lovondi Jordan serve alongside others with varying term expirations. Meetings are held on the second Tuesday of every month at 6 PM at Kewanee City Hall, and the public is invited to attend. The public can stay informed by reviewing agendas and minutes online. For inquiries or to get involved, contact City Clerk Kasey Mitchell at kmitchell@cityofkewanee.net or visit the commission's Facebook page.
We cannot wait to welcome attendees to a popular IADC meeting location – the historic, quaint Québec City – for the 2025 Annual Meeting. In this location series episode, IADC Speaks Host Robin Linley (Blake, Cassels & Graydon LLP) speaks with fellow member and area expert Ariane Bisaillon (Blake, Cassels & Graydon LLP) about all things Québec City. This quick episode shares fun facts about the city, recommendations of family-friendly activities, and food/restaurant suggestions.
In the wake of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® put together an X Spaces discussion hosted by Stephen Liu, MD, and Joshua Sabari, MD, to highlight the most intriguing and practice-changing lung cancer abstracts. Discussed topics ranged from long-term follow-up with commonplace therapies to an analysis of what time of day is the best to administer immunochemotherapy. Liu, an associate professor of Medicine at Georgetown University, and the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Sabari, an assistant professor in the Department of Medicine at the NYU Grossman School of Medicine, and the director of High Reliability Organization Initiatives at the Perlmutter Cancer Center, shared expert insights on the latest non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) breakthroughs. Trials of note that they discussed included: The phase 3 DeLLphi-304 trial (NCT05740566) - Tarlatamab (Imdelltra) versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304.1 The phase 3 IMforte trial (NCT05091567) - Lurbinectedin (Zepzelca; lurbi) + atezolizumab (Tecentriq; atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial.2 The phase 3 CheckMate 816 trial (NCT02998528) - Overall survival with neoadjuvant nivolumab (Opdivo; NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.3 The phase 3 PACIFIC15 trial (NCT05549037) - Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non–small cell lung cancer.4 The phase 3 Beamion LUNG-1 trial (NCT04886804) - Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non–small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial.5 The phase 3 ARTEMIA trial (NCT06472245) - Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non–small cell lung cancer and secondary resistance to immunotherapy. References Rudin C, Mountzios G, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304. J Clin Oncol. 2025;43(suppl 17):LBA8008. doi:10.1200/JCO.2025.43.17_suppl.LBA8008 Paz-Ares L, Borghaei H, Liu SV, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial. J Clin Oncol. 2025;43(suppl 16):8006. doi:10.1200/JCO.2025.43.16_suppl.8006 Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab + chemotherapy in patients with resectable NSCLC in CheckMate 816. J Clin Oncol. 2025;43(suppl 17):LBA8000. doi:10.1200/JCO.2025.43.17_suppl.LBA8000 Zhang Y, Huang Z, Zeng L, et al. Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. J Clin Oncol. 2025;43(suppl 16):8516. doi:10.1200/JCO.2025.43.16_suppl.8516 Sabari JK, Nadal E, Hendriks L, et al. Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial. J Clin Oncol. 2025;43(suppl 16):8620. doi:10.1200/JCO.2025.43.16_suppl.8620 Liu SV, Guibert C, Tostivint EP, et al. Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy. J Clin Oncol. 2025;43(suppl 16):TPS8651. doi:10.1200/JCO.2025.43.16_suppl.TPS8651
Fertility & Sterility on Air is at the Pacific Coast Reproductive Society 2025 Annual Meeting in Indian Wells, CA! In this episode, our hosts Kate Devine and Micah Hill talk with: PCRS leadership Alexander Quaas and Jason Franasiak discussing this and future conferences (0:41), Shannon Rainsford about Protamine 2 deficiency (9:54), Andria Besser about mosaic and segmental PGT-A results (16:15), Emily Patterson about comprehensive carrier screening (28:35), Esther Chung about a low-cost progestin protocol for oocyte cryopreservation (32:23) and Howard Li discussing the feasibility of microwave drying for long-term storage of human oocytes at non-freezing temperatures (41:28). View Fertility and Sterility at https://www.fertstert.org/
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Vi-Anne Antrum, System Chief Nursing Officer, Cone Health. She shares how Cone Health is using AI to improve patient engagement and operational efficiency, while emphasizing the importance of grace, curiosity, and frontline voices in navigating today's healthcare challenges.
Featuring perspectives from Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi A Jänne, Dr Suresh S Ramalingam, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics: Introduction (0:00) Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Dr Yu (1:47) EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents — Dr Sabari (23:48) Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Ramalingam (45:16) Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC — Dr Goldman (1:03:56) Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC — Prof Girard (1:24:40) Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Jänne (1:43:46) CME information and select publications
Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode. Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here. Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months. The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured? Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients. And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's guest: Dr. John Sweetenham Dr. Marc Braunstein @docbraunstein Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Marc Braunstein: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp Speakers' Bureau: Janssen Oncology Research Funding (Institution): Janssen, Celgene/BMS
Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here.
In this episode, Craig speaks with Chris Hefner to discuss their experiences at the Southern Baptist Convention's annual meeting. They explore the structure and governance of the Southern Baptist Convention, the significance of the Cooperative Program, and the highlights from the meeting, including updates on missionaries and the role of seminaries. They also address the North American Mission Board's efforts in church planting and disaster relief, the function of the Executive Committee, and the current scrutiny facing institutions within the convention. Chris and Craig also discuss the importance of integrity and transparency in leadership within the Southern Baptist Convention (SBC), particularly focusing on the Ethics and Religious Liberties Commission (ERLC). They explore the challenges faced by the ERLC, its role in representing Southern Baptists in political matters, and the tensions that arise from differing views on its purpose. The discussion also touches on the ongoing debates regarding women in pastoral roles, the future of the SBC's governing documents, and the perception of a liberal drift within the convention. Ultimately, they emphasize the importance of unity, community, and worship among Southern Baptists despite controversies.TakeawaysThe Southern Baptist Convention operates through local churches and associations.The Cooperative Program supports missions and theological education.The annual meeting is the world's largest business meeting.Over 400 new missionaries were put on the field this year.Southern Baptist seminaries are financially healthy and conservative in theology.The North American Mission Board focuses on church planting and disaster relief.Southern Baptists are active in disaster relief efforts across the country.The Executive Committee manages the finances and operations of the convention.Institutional trust is a significant issue in today's cultural climate. Integrity and transparency are crucial for leadership.The ERLC has faced significant criticism over the years.The ERLC serves as the voice of Southern Baptists in Washington, D.C.There is tension between the ERLC's role and the views of Southern Baptists.Disagreements exist on the purpose and direction of the ERLC.The SBC's governing documents are under scrutiny regarding women's roles.Unity is essential despite differing opinions within the convention.Social media often amplifies division rather than unity.Worship and community are vital aspects of the SBC's gatherings.Chapters00:00Introduction to the Southern Baptist Convention02:24Understanding the Structure of Southern Baptist Governance05:10The Cooperative Program: A Foundation for Missions07:17Highlights from the Annual Meeting: Missionary Updates10:36The Role of Southern Baptist Seminaries14:13North American Mission Board: Church Planting and Disaster Relief18:30The Executive Committee: Governance and Oversight22:48Addressing Institutional Scrutiny and Trust Issues25:04Integrity and Transparency in Leadership26:34The Role and Challenges of the ERLC28:27Understanding the ERLC's Purpose30:04The Tension Between ERLC and Southern Baptists32:31Debating the ERLC's Direction35:02Women in Pastoral Roles and the SBC38:00The Future of the SBC's Governing Documents40:05Unity Amidst Controversy43:24Addressing Perceptions of Liberal Drift46:45Worship and Community at the SBC Convention
Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely. So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely. So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point. So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely. Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers: Dr. John Sweetenham Dr. Erika Hamilton @erikahamilton9 Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: No relationships to disclose Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics
The Annual Meeting of the New Champions 2025 - AMNC25 - will bring together leaders from government, business and academia, along with innovators and representatives from international organizations, media and civil society. In this special episode produced in collaboration with Caixin Global, World Economic Forum Managing Director Mirek Dusek sets the scene for the 'Summer Davos' in Tianjin, China. And Jen Zhu Scott, founding partner of IN. Capital, gives an insider's view of China and its place in the world. Co-hosted by Li Xin, managing editor of Caixin Global. Catch up on all the action from AMNC25 at and across social media using the hashtag #AMNC25. Links: AMNC25: Caixin Global: Related podcasts: Check out all our podcasts on : - - : - : - : Join the :
This special episode was recorded at the mid-year symposium of the International Society of Pharmacovigilance (ISoP), 14–15 May 2025. Held in Uppsala, Sweden, the theme of the symposium was Improving information capture for safer use of medicines. The episode is an abridged recording of the concluding fireside chat, where Angela Caro Rojas (president of ISoP), Linda Härmark (director of the Drug Safety Research Unit in the UK), Ghita Benabdallah (national pharmacovigilance centre of Morocco, member of the IsoP advisory board), and Daniele Sartori (senior pharmacovigilance researcher at Uppsala Monitoring Centre), discuss patient engagement in pharmacovigilance.The symposium was a collaboration between ISoP and UMC. Want to know more?Visit the official website of the 2025 ISoP Mid-Year Symposium to learn more about its sessions, speakers and chairs. Not patient but im-patient – read about Sara Riggare's research on patient engagement and other topics.Listen to Henry Zakumumpa talk about his study on adverse event reporting quality in Uganda in this 2025 episode of Drug Safety Matters.Read about the PhD project of Tommy Emil Dzus, Improving causality assessment in pharmacovigilance for safe and sustainable use of medicines in health emergencies, at Oslo Metropolitan University, Norway.Sabine Koch is Head of the Department of Learning, Informatics, Management and Ethics (LIME), at Karolinska Institutet, Stockholm.Details on Mikael Hoffman's research can be found on his profile page on ResearchGate.Take a look at what's in store for participants at the 24th Annual Meeting of ISoP in Cairo, on October 24–27, 2025.Visit the websites of the Drug Safety Research Unit (DSRU), ISoP, Centre Anti Poison et Pharmacovigilance du Maroc, and Uppsala Monitoring Centre, to find out more about their work. Join the conversation on social mediaFollow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we work to advance medicines safety.
Caixin Global partners with Radio Davos to produce a podcast ahead of next week's World Economic Forum Annual Meeting of the New Champions in Tianjin. The Annual Meeting of the New Champions 2025 — AMNC25 — will bring together leaders from government, business and academia, along with innovators and representatives from international organizations, media and civil society. In this special episode (transcript) produced in collaboration with Caixin Global, World Economic Forum Managing Director Mirek Dušek sets the scene for “Summer Davos” in Tianjin, China. And Jen Zhu Scott, founding partner of IN. Capital, gives an insider's view of China and its place in the world. Guests: Mirek Dušek, Managing Director, Chief Business Officer and Head of Global Programming, World Economic Forum Li Xin, Managing Editor and Managing Director, Caixin Global Jen Zhu Scott, Founding Partner, IN. Capital Hosted by: Robin Pomeroy, Podcast Editor, World Economic Forum Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a 66% discount. Group discounts are available — contact us for a customized plan.
The Annual Meeting of the New Champions 2025 - AMNC25 - will bring together leaders from government, business and academia, along with innovators and representatives from international organizations, media and civil society. In this special episode produced in collaboration with Caixin Global, World Economic Forum Managing Director Mirek Dusek sets the scene for the 'Summer Davos' in Tianjin, China. And Jen Zhu Scott, founding partner of IN. Capital, gives an insider's view of China and its place in the world. Co-hosted by Li Xin, managing editor of Caixin Global. Catch up on all the action from AMNC25 at wef.ch/amnc25 and across social media using the hashtag #AMNC25. Links: AMNC25: https://www.weforum.org/meetings/annual-meeting-of-the-new-champions-2025/ Caixin Global: https://www.caixinglobal.com/ Related podcasts: Getting sustainable, secure and equitable power to the people - how's the global energy transition going? Stock markets and supermarkets: how business is deploying AI “Trillions of dollars added to the economy” - Google's chief economist on the macro impact of AI Check out all our podcasts on wef.ch/podcasts: YouTube: - https://www.youtube.com/@wef/podcasts Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552 Join the World Economic Forum Podcast Club: https://www.facebook.com/groups/wefpodcastclub
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Dr. Sandra Scott, CEO, One Brooklyn Health. Dr. Scott discusses her focus on improving the patient experience, embracing workforce innovation, and using empathy and technology to shape a more effective and human-centered future in healthcare.
Today on Truth in Politics and Culture, I will give a quick recap of the highlights of the Southern Baptist Convention Annual meeting, President Trump comes home early from the G7 Summit to address the Israeli/Iranian conflict, J.J. Spaun fulfills his responsibility as a dad and wins the U.S. Open, the terrible murders and wounding of Minnesota lawmakers takes center stage as a suspect is captured, and how should Christians engage in a toxic culture and political environment?
"Certainly, I've been anxious about data...I did an experiment, I put a lot of time into it, I'm hoping to get good results...we all know that feeling, right? The stakes are just so different here...this kid's life depends on whether this experiment worked." --Kiran Musunuru, MD, PhD One of the highlights of the ASGCT 28th Annual Meeting was the announcement on May 15 of a historic medical breakthrough: a child diagnosed with a rare genetic disorder had been successfully treated for the first time with a customized CRISPR gene editing therapy. The infant, KJ Muldoon, was born with a rare metabolic disease called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. When he was just six months old, KJ received his personalized therapy at the Children's Hospital of Philadelphia (CHOP), where ASGCT Members Kiran Musunuru, MD, PhD; and Rebecca Ahrens-Nicklas, MD, PhD; led the group of researchers who developed KJ's treatment. KJ is now growing and thriving. He recently left the hospital where he has spent the majority of his life. And the day after presenting the research that led to this first-of-its-kind development, Dr. Musunuru told us that there was so much more to the story. Listen to our first episode of Soundbites of the Annual Meeting with Dr. Kiran Musunuru. Did you attend the 28th Annual Meeting? Watch all sessions, including Dr. Musunuru's presentation, on demand on the virtual meeting platform through July 18! Not a member? Join now and receive 19 months of membership for the price of 12. Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
Methane is a potent greenhouse gas that traps energy far more efficiently than carbon dioxide. Reduction of methane emissions is thus essential to slowing climate change, and livestock are a major source of these emissions. Dr. Phil Cardoso talks with Dr. Alex Hristov of Penn State University about nutritional strategies for mitigating production of methane by dairy cattle. They discuss the effectiveness of several different feed additives at reducing methane emissions and their effects on DMI and milk production.Links to papers and other sources mentioned in this episodeHristov et al. 2022. Symposium review: Effective nutritional strategies to mitigate enteric methane in dairy cattle.DOI: 10.3168/jds.2021-21398https://www.journalofdairyscience.org/article/S0022-0302(22)00392-7/fulltextInternational Methane Emissions Observatory (IMEO) https://www.unep.org/explore-topics/energy/what-we-do/imeoJoint EU-US Statement on the Global Methane Pledge https://ec.europa.eu/commission/presscorner/detail/en/statement_21_5206Hristov et al. 2015, An inhibitor persistently decreased enteric methane emission from dairy cows with no negative effect on milk production.DOI: 10.1073/pnas.1504124112https://www.pnas.org/doi/10.1073/pnas.150412411273rd Annual Meeting of EAAP. Porto, Portugal, September 5–9 2022.https://eaap2022.org/docs/Final_Programme_EAAP22.pdf#page=53Arndt et al. 2022, Full adoption of the most effective strategies to mitigate methane emissions by ruminants can help meet the 1.5 °C target by 2030 but not 2050.DOI: 10.1073/pnas.2111294119https://www.pnas.org/doi/10.1073/pnas.2111294119Duin et al. 2016, Mode of action uncovered for the specific reduction of methane emissions from ruminants by the small molecule 3-nitrooxypropanol.DOI: 10.1073/pnas.1600298113Pitta et al. 2022, The effect of 3-nitrooxypropanol, a potent methane inhibitor, on ruminal microbial gene expression profiles in dairy cows.DOI: 10.1186/s40168-022-01341-9https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01341-9FAO-IPCC Expert Meeting on Climate Change, Land Use and Food Security. Rome, Italy January 23–25 2017.https://www.fao.org/3/i7068e/i7068e.pdfHristov and Melgar 2020, Short communication: Relationship of dry matter intake with enteric methane emission measured with the GreenFeed system in dairy cows receiving a diet without or with 3-nitrooxypropanol.DOI: 10.1017/S1751731120001731https://www.sciencedirect.com/science/article/pii/S1751731120001731?via%3Dihubhttps://globalresearchalliance.org/research/livestock/networks/feed-nutrition-network/Hammond et al. 2016, Review of current in vivo measurement techniques for quantifying enteric methane emission from ruminants.DOI: 10.1016/j.anifeedsci.2016.05.018https://www.sciencedirect.com/science/article/abs/pii/S0377840116302048Roque et al. 2019, Inclusion of Asparagopsis armata in lactating dairy cows' diet reduces enteric methane emission by over 50 percent.https://www.sciencedirect.com/science/article/abs/pii/S0959652619321559DOI: 10.1016/j.jclepro.2019.06.193Martins et al. 2022, Effects of feeding method and frequency on lactationalperformance and enteric methane emission in dairy cows.https://www.adsa.org/Portals/0/SiteContent/Docs/Meetings/2022ADSA/Abstracts_BOOK_2022.pdf#page=79Martins et al. 2022, Effects of botanical preparations on lactational perfor-mance and enteric methane emission in dairy cows.https://www.adsa.org/Portals/0/SiteContent/Docs/Meetings/2022ADSA/Abstracts_BOOK_2022.pdf#page=131
This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Lynn Fulton, Chief Executive Officer of Maui Health. Lynn shares how she's fostering leadership development, addressing critical workforce challenges unique to island healthcare, and building sustainable pipelines to support both staff and community through initiatives like “grow your own” programs and innovative housing solutions.
On this episode of Brand & New, INTA Chief Policy Officer Heather Steinmeyer sits down with David Gooder, INTA's newly appointed Senior Advisor and former Commissioner for Trademarks at the United States Patent and Trademark Office (USPTO). In this insightful conversation recorded at INTA's 2025 Annual Meeting in San Diego, California, Ms. Steinmeyer and Mr. Gooder explore the evolving role of global intellectual property (IP) offices, as well as the delicate balance IP offices must strike between serving their users and advancing broader competitiveness goals. Mr. Gooder shares his unique perspective from both sides of the IP ecosystem, having worked as chief trademark counsel at Jack Daniels Properties before leading the USPTO's trademark operations through five transformative years. As he transitions into his new role helping INTA deepen collaboration with IP offices worldwide, this conversation offers valuable insights into the future of IP protection and the strategic importance of trademark systems in fostering global competitiveness. Resources: About David Gooder INTA Welcomes David Gooder as Senior Advisor (INTA, May 2025) David Gooder to depart USPTO (USPTO, February 2025)
In this episode of SurgOnc Today, Dr. Olga Kantor from Brigham and Women's Hospital and Dr. Taiwo Adesoye from MD Anderson Cancer Center discuss the breast track highlights of the SSO 2025 Annual Meeting, focusing on a few potentially practice changing trials presented at the meeting. In case you missed the meeting, be sure to check out the On Demand content, now available at https://learn.surgonc.org/.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Kathy Kelly, Market Chief Executive Officer, Kindred Hospitals. Kathy shares her journey from the supplier side of healthcare to leading long-term acute care hospitals, emphasizing physician realignment, care quality, and workforce engagement.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Sarah Matney, Senior Vice President, Clinical Services and Chief Nursing Officer, Connecticut Children's. Sarah shares insights on workforce stabilization, mentorship programs to strengthen the future healthcare pipeline, and the importance of flexibility and engagement in retaining top talent.
Welcome to Part Two of our coverage of the Consortium of Multiple Sclerosis Centers annual meeting! In this week's episode, Dr. John DeLuca shares research that has identified an effective behavioral treatment for MS-related fatigue. Dr. Brian Sandroff discusses how MS rehabilitation has evolved and then answers some of your questions about exercise and MS. And Kristine Werner Ozug, a member of the RealTalk MS team and someone who lives with MS, shares her perspective on the sessions and presentations she attended at CMSC. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Part 2 of our coverage from the 2025 Consortium of MS Centers Annual Meeting :22 Dr. John DeLuca shares his research, which has identified an effective behavioral treatment for MS-related fatigue 1:15 Dr. Brian Sandroff discusses how MS rehabilitation has evolved and answers some of your questions 8:34 Kristine Werner Ozug shares her perspective on the sessions and presentations she attended at CMSC 19:34 Share this episode 31:13 Have you downloaded the free RealTalk MS app? 31:34 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/406 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 406 Guests: Dr. John DeLuca, Dr. Brian Sandroff, and Kristine Werner Ozug Privacy Policy
This week, we welcome Cornell Winston (current President of the American Association of Law Libraries) and Jenny Silbiger (President‑Elect). Speaking from sunny San Diego and O‘ahu's courthouse halls, the duo joins the show to preview AALL's 2025 Annual Meeting in Portland, Oregon—and to talk candidly about the challenges and opportunities facing the legal‑information profession during a time of rapid technological and political flux.Cornell and Jenny explain why open communication has become a strategic imperative for AALL. Although board books have long been public, they are doubling down on proactive updates—through e‑briefings, “Know‑It‑AALL” newsletters, and 80‑plus committee channels—because members crave clarity when the profession feels under siege. Their message is simple: phone numbers and inboxes are open; no question is off‑limits. The leaders frame transparency not as a defensive posture, but as an invitation to pull every member into the conversation and decision‑making process.The discussion then turns to the vacant Government Relations role—often seen as AALL's front line in Washington. Cornell reassures listeners that, despite the hiring gap, advocacy has never left the stage: the Government Relations Committee partners with ALA and other allies, tracks executive‑order whiplash, and issues public statements on IMLS funding or Library of Congress appointments. While lobby dynamics have shifted since COVID‑era restrictions, AALL continues to file comments, weigh amicus briefs, and equip members to speak up in their own jurisdictions until the position is refilled.Next, the hosts probe changes to the volunteer pipeline. Under the new process, virtually every member who raises a hand gets a seat—whether on a jury, committee, or the coveted Annual Meeting Program Committee. Headquarters now monitors overlapping appointments to spread opportunities and ensure early‑career librarians experience the career‑shaping mentorship Greg once received from the late Bob Oakley. Jenny underscores that engagement options range from micro‑tasks to multi‑year leadership roles, accommodating both time‑pressed newcomers and seasoned veterans.Turning to the July 19‑22 conference itself, Cornell shares upbeat registration numbers, hotel tips, and—importantly—news of no late‑registration fee increase. Portland's light‑rail pass, tax‑free shopping, and Nike/Columbia/Adidas discounts sweeten the trip, but the intellectual draw is formidable: 65‑plus programs, four pre‑conference workshops, and a cross‑pollinated AI track that unites academic and private‑sector librarians. Keynote speaker Roosevelt Weeks, renowned for transforming Austin Public Library into a nationally acclaimed, radically welcoming space, will challenge attendees to double down on access and inclusion.Asked for their “biggest challenge” predictions, Jenny cites the breakneck pace of AI and the resulting imperative to preserve integrity in an era of deepfakes and data deluge. Cornell echoes the warning: librarians must remain society's trusted validators and proclaim that expertise without apology. As the gavel passes in Portland, Jenny's presidential agenda crystallizes around three goals—meeting members where they are, converting dialogue into strategic action, and leaving the profession stronger for the next generation. Whether you are a long‑time AALL stalwart or a first‑time volunteer, this episode is a reminder that the future of legal information will be shaped by those who show up, speak up, and keep the channels open.Listen on mobile platforms: Apple Podcasts | Spotify | YouTube[Special Thanks to Legal Technology Hub for their sponsoring this episode.] Blue Sky: @geeklawblog.com @marlgebEmail: geekinreviewpodcast@gmail.comMusic: Jerry David DeCicca Transcript
This week's episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Wendi Hulett, Chief Nursing Officer at Lincoln County Medical Center – Presbyterian Healthcare Services. She discusses how her team drastically reduced nurse turnover through a rapid hire process and shares insights on navigating workforce expectations and the evolving role of AI in nursing.
Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid Services, recently convened in Washington D.C. for the Medical Device Manufacturers Association (MDMA) Annual Meeting. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott, Nate Beaton, and Bill McConagha, and associate Danny Machado share their key takeaways from the meeting, including compliance hot topics and what the industry can expect in terms of regulatory enforcement in 2025. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200
As we are well into the first half of the year – and here at INFORMS we have packed a lot into these first few months – now is a terrific time to circle back and check in with the 2025 INFORMS President Dave Hunt. We kicked off a brand-new year of Resoundingly Human podcasts back in January with a special double header featuring Dave where we discussed both his goals and objectives relating to INFORMS as well as heard his perspective on the unique and exciting ways INFORMS members are going to continue to help make smarter decisions for a better world.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Lynne Fiscus, President and Chief Executive Officer of UNC Physicians Network. She shares insights on building a sustainable clinical workforce through initiatives like the O2 onboarding and optimization team, and highlights how UNC Health is prioritizing flexibility to reduce burnout and improve care delivery.
This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Heather Resseger, Senior Vice President, Chief Hospital Operations Officer and Chief Nursing Officer at NorthBay Health. She discusses her organization's Magnet recertification, workforce engagement strategies, and the critical need to address behavioral health as a core component of improving care delivery.
Segment 1: • The Southern Baptist Convention heads to Dallas—and tensions are rising. • Debates over the ERLC's purpose and women's roles in the church resurface. • Millions of dollars are at stake—are they fueling mission or bureaucracy? Segment 2: • Todd questions if the SBC is investing more in politics than people. • Al Mohler even questions the ERLC's effectiveness—so what now? • What if those dollars were redirected to direct gospel work? Segment 3: • The SBC wants unity—but disagreements over essentials threaten that goal. • True unity can't be built on compromise—it must be rooted in truth. • The Lord's Table reminds us: sin is deep, but grace is deeper. Segment 4: • As the SBC meets, deeper questions loom: Are we majoring in minors? • MacArthur and Sproul once showed how to disagree without dividing. • Maybe it's time to refocus on the gospel and rediscover love for God. ___ Thanks for listening! Wretched Radio would not be possible without the financial support of our Gospel Partners. If you would like to support Wretched Radio we would be extremely grateful. VISIT https://fortisinstitute.org/donate/ If you are already a Gospel Partner we couldn't be more thankful for you if we tried!
Last week in Phoenix, Arizona, the Consortium of Multiple Sclerosis Centers (CMSC) held its annual meeting, and we had a chance to talk with some of the top MS experts in the world. Welcome to Part One of our coverage! First, you'll hear Dr. Kathy Zackowski, the National MS Society's Associate Vice-President of Research, share her overview of the sessions and presentations that especially stood out to her. Then, you'll hear Dr. Stephen Krieger as he expands on one of the most interesting and provocative presentations at the conference. Dr. Krieger headed up a panel of experts that explained how the terms used to describe MS today (relapsing-remitting, secondary progressive, and primary progressive) are no longer adequate and then offered answers to the question, "If MS is one disease, what does that mean for clinical conversations?". We have a lot to talk about! Are you ready for RealTalk MS??! This Week: From the 2025 Consortium of MS Centers Annual Meeting :22 Dr. Kathy Zackowski shares an overview of the sessions and presentations that caught her eye 1:08 Dr. Stephen Krieger discusses seeing MS as one disease 17:11 Share this episode 31:58 Have you downloaded the free RealTalk MS app? 32:18 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/405 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 405 Guests: Dr. Kathy Zackowski and Dr. Stephen Krieger Privacy Policy
This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Salman Ali, CEO and Co-Founder of Kouper Health. He shares how Kouper is using generative AI to streamline care transitions, reduce readmissions, and improve follow-up rates—offering actionable insights on implementation, integration, and ROI for health system leaders.This episode is sponsored by Kouper Health.
© 2020-2025 Ivy Podcast Discovery LLC
